Akebia Therapeutics Inc
NASDAQ:AKBA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Akebia Therapeutics Inc
NASDAQ:AKBA
|
US |
Intrinsic Value
The intrinsic value of Akebia Therapeutics Inc (AKBA) under the Base Case is 2.1228 USD per share.
Compared with the current market price of 0.6604 USD, the stock appears
Undervalued by 69% .
The intrinsic value is calculated using the DCF method. The model assumes revenue returns to growth: about 0% a year over the next five years, after falling about 4% a year over the last five years. If revenue grew at its five-year pace of -4%, the estimate would be about $1.50. The value of the years after 2031 is tied to revenue, so margins count only until then.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Akebia Therapeutics Does
Akebia Therapeutics is a drug company focused on kidney disease. It develops and sells prescription medicines for people with chronic kidney conditions, especially patients who have anemia tied to kidney failure or treatment. Its products are used through doctors and dialysis centers, so the company’s customers are the medical providers and health systems that prescribe and dispense the drugs to patients.
- Headquarters
- United States of America US
- Employees
- 194
- IPO date
- Mar 20, 2014
Revenue & Expenses Breakdown
Akebia Therapeutics Inc
Earnings Waterfall
Akebia Therapeutics Inc
The intrinsic value for Akebia Therapeutics Inc (AKBA) under the Base Case is 2.1228 USD.
Compared with the current market price of 0.6604 USD, the stock appears Undervalued by 69% .